Expertise in
4
conditions

Dr. Jonathan Liss

Neurology
Jonathan L. Liss MD Neurology PC
7196 North Lake Dr Ste A, 
Columbus, GA 
Expertise in
4
conditions
Jonathan L. Liss MD Neurology PC
7196 North Lake Dr Ste A, 
Columbus, GA 

Overview

Jonathan Liss is a Neurologist in Columbus, Georgia. Dr. Liss is highly rated in 4 conditions, according to our data. His top areas of expertise are Cerebellar Degeneration, Neuronal Intranuclear Inclusion Disease (NIID), Alzheimer's Disease, and Dementia.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Neurology

Licenses

Psychiatry & Neurology in GA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Jonathan L. Liss MD Neurology PC
7196 North Lake Dr Ste A, Columbus, GA 31909

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: July 31, 2024
Intervention Type: Drug, Other
Study Drug: Bryostatin I
Study Phase: Phase 2
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease
A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

4 Total Publications

Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: August 19, 2025
Similar Doctors
Expertise in
45
conditions
Dr. Reinaldo D. Verson
Neurology
Expertise in
45
conditions
Dr. Reinaldo D. Verson
Neurology

St. Francis Columbus Clinic

610 19th Street, Ste300, 
Columbus, GA 
 (5.1 miles away)
706-322-7884
Experience:
37+ years
Languages Spoken:
English, French, Mandarin, Spanish
See accepted insurances

Reinaldo Verson is a Neurologist in Columbus, Georgia. Dr. Verson has been practicing medicine for over 37 years is highly rated in 45 conditions, according to our data. His top areas of expertise are Memory Loss, Primary Orthostatic Tremor, Autosomal Dominant Partial Epilepsy with Auditory Features, and Migraine.

Expertise in
24
conditions
Dr. Jagdish Sidhpura
Neurology
Expertise in
24
conditions
Dr. Jagdish Sidhpura
Neurology

Office

700 Center St Ste 304, 
Columbus, GA 
 (6.0 miles away)
706-322-0176
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jagdish Sidhpura is a Neurologist in Columbus, Georgia. Dr. Sidhpura is highly rated in 24 conditions, according to our data. His top areas of expertise are Transient Ischemic Attack (TIA), Seizures, Generalized Tonic-Clonic Seizure, and Memory Loss.

Expertise in
4
conditions
Dr. Bhanu Gogia
Neurology
Expertise in
4
conditions
Dr. Bhanu Gogia
Neurology

Piedmont Columbus Regional Midtown

710 Center St, 
Columbus, GA 
 (5.0 miles away)
706-571-1748
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bhanu Gogia is a Neurologist in Columbus, Georgia. Dr. Gogia is highly rated in 4 conditions, according to our data. Her top areas of expertise are Miller-Fisher Syndrome, Guillain-Barre Syndrome, Stiff Person Syndrome, and Brain Tumor.

Frequently Asked Questions about Dr. Jonathan Liss

How do I make an appointment with Dr. Jonathan Liss?

You can book an appointment with Dr. Jonathan Liss by calling their office at 706-327-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan Liss a top-rated expert for Cerebellar Degeneration?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan Liss is classified as an Distinguished expert for Cerebellar Degeneration, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan Liss specialize in?

While Dr. Jonathan Liss is a Neurology, they have specific expertise in Cerebellar Degeneration, Neuronal Intranuclear Inclusion Disease (NIID), and Alzheimer's Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Jonathan Liss participate in research or clinical trials?

Yes. Dr. Jonathan Liss has published 4 articles and abstracts on conditions like Cerebellar Degeneration. You can view a list of Dr. Jonathan Liss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan Liss accept my insurance?

Dr. Jonathan Liss accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 706-327-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liss's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile